Sydnexis
Del Mar, US · Founded 2014 · Delaware corporation · 19 employees on LinkedIn · 3 known investors
Find your way into Sydnexis
124 people in our graph share verified history with the Sydnexis team — schools, employers, funds. One of them is your warm intro.
Nick Kaiserunlockedknows Patrick Johnson · together at UC Santa Barbara (overlapped)
knows the team · via Sydnexis
×8knows the team · via UC Santa Barbara
×2knows the team · via Multiple
Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia. The company focuses on pediatric ophthalmology and children's eye care.
Founders & leadership
Sydnexis was founded in 2014 by Patrick Johnson.
PJ
Patrick JohnsoninFounder · PresidentPatrick Johnson is an executive with experience in pharmaceutical business development, having led business development for eye care and drug delivery at Allergan, along with roles in M&A, fundraising, and drug development across startup and large-cap pharma companies. He holds multiple US patents and has published approximately 20 peer-reviewed articles in scientific journals.
MJ
Mary Jaqueline JohnsonExecutive
MJ
Mary Jacqueline JohnsonNamed on SEC filing
KJ
Kevin JohnsonNamed on SEC filing
GO
Greg OstrowNamed on SEC filing
KW
Kenneth WidderNamed on SEC filing
Board
ZS
PS
JK
TS
Tyler StowaterBoard director
JB
RL
Richard LindstromBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$72.3M disclosed across 4 rounds · 2017–2025
▶$20MraisedApr 2025 · 23 investors · OtherRule 506(b)
▶$20MraisedApr 2025 · 23 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Mary Jaqueline JohnsonExecutive Officer
- Zach ScheinerDirector
- Patrick JohnsonExecutive Officer, Promoter
- Perry SternbergExecutive Officer, Director, Promoter
- Jeffry K. WeinhuffDirector
- Tyler StowaterDirector
- Juliet BakkerDirector
- Richard LindstromDirector
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$999.8KraisedMay 2024 · 30 investors · OtherRule 506(b)
▶$999.8KraisedMay 2024 · 30 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Richard LindstromDirector
- Zach ScheinerDirector
- Juliet BakkerDirector
- Mary Jaqueline JohnsonExecutive Officer
- Patrick JohnsonExecutive Officer, Promoter
- Jeffry K. WeinhuffDirector
- Tyler StowaterDirector
- Offering amount
- $8.5M
- Amount sold
- $999.8K
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45.8MraisedAug 2021 · 26 investors · PharmaceuticalsRule 506(b)
▶$45.8MraisedAug 2021 · 26 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Tyler StowaterDirector
- Kenneth WidderExecutive Officer, Director, Promoter
- Richard LindstromDirector
- Patrick JohnsonExecutive Officer, Promoter
- Mary Jacqueline JohnsonExecutive Officer
- Zachary ScheinerDirector
- Greg GrunbergDirector
- Jeffry K. WeinhuffDirector
- Offering amount
- $45.8M
- Amount sold
- $45.8M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedOct 2017 · 6 investors · PharmaceuticalsRule 506(b)
▶$5.5MraisedOct 2017 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mary Jacqueline JohnsonExecutive Officer
- Kevin JohnsonDirector
- Greg OstrowExecutive Officer, Director
- Zachary ScheinerDirector
- Kenneth WidderExecutive Officer, Director
- Offering amount
- $35M
- Amount sold
- $5.5M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Warby Parker42 shared keywordsWarby Parker is a direct-to-consumer eyewear retailer offering prescription eyeglasses, sunglasses, contacts, and eye exams at affordable prices, with a home try-on service and flexible return policy.
Pair Eyewear33 shared keywordsPair Eyewear designs and sells prescription and non-prescription eyeglasses with swappable frame tops that allow customers to change styles. The company manufactures frames and lenses in-house in the U.S. and targets consumers seeking affordable, customizable eyewear.
Companies competing with Sydnexis for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Sydnexis do?
- Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia. The company focuses on pediatric ophthalmology and children's eye care.
- Who founded Sydnexis?
- Sydnexis was founded by Patrick Johnson in 2014.
- Who are Sydnexis's investors?
- Sydnexis's investors include Longitude Capital, RA Capital, Visionary Ventures.
- How much funding has Sydnexis raised?
- Sydnexis has disclosed $72.3M raised across 4 rounds.
- Where is Sydnexis headquartered?
- Sydnexis is headquartered in Del Mar, US.